Affymax, Inc. Completes Enrollment in PEARL 2, the Second of Four Phase 3 Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe.